Sugi Predict

Sugi Predict / Compounds / SCHEMBL17484143

SCHEMBL17484143

SCHEMBL17484143

CC(C)C(NC(=O)OC(C)(C)C)C(=O)NC1CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.55
▸ CTSS P25774 2/20 0.55
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ PREP P48147 1/20 0.45
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CA2 P00918 2/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ ELANE P08246 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ EPHX1 P07099 1/20 0.41
▸ TRPA1 O75762 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25069103 0.94 CTSK (0.52) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL1953964 0.94 HDAC4 (0.54) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL1953962 0.94 HDAC4 (0.54) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL27600919 0.93 HDAC4 (0.56) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL27600918 0.93 HDAC4 (0.56) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL15359462 0.91 CTSK (0.47) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL4704612 0.84 KMT2A (0.53) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL18869105 0.83 CTSK (0.54) CTSKCTSSKMT2AMEN1PREP
SCHEMBL20732867 0.83 HDAC4 (0.48) CTSKCTSSHDAC4HDAC1HDAC6
SCHEMBL28407302 0.83 HDAC4 (0.48) CTSKCTSSHDAC4HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
CN-109369635-B Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition 赛克里翁治疗有限公司 2023-06-30 — — CN disclosed
US-20230106002-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. 2023-04-06 — — US disclosed
US-20230053342-A1 IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2023-02-23 — — US disclosed
CN-109384778-B Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder 赛克里翁治疗有限公司 2022-12-13 — — CN disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 — — EP disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 — — EP disclosed
EP-3660013-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2022-01-19 — — EP disclosed
US-11207323-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-12-28 — — US disclosed
CN-109369635-A Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof 铁木医药有限公司 2019-02-22 — — CN disclosed
US-10183021-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2019-01-22 — — US disclosed
CN-108912111-A compounds and pharmaceutical compositions 铁木医药有限公司 2018-11-30 — — CN disclosed
CN-105408328-B sGC stimulators 铁木医药有限公司 2018-11-16 — — CN disclosed
US-20170137439-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-18 — — US disclosed
US-20170136019-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-18 — — US disclosed
US-9586937-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2017-03-07 — — US disclosed
US-20160347738-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-12-01 — — US disclosed
US-9481689-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2016-11-01 — — US disclosed
US-20160031903-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106002-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885
US-20170137439-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885
US-11207323-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885
US-20230053342-A1 IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, SLC5A11, CYP51A1 CTSK 3023/4885CTSS 3795/4885HDAC4 2467/4885
US-20160347738-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885
US-10183021-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885
US-20170136019-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885
US-20160031903-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 CTSK 3070/4885CTSS 2687/4885HDAC4 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.